Abstract
The First-in-Class UBA1 Inhibitor, TAK-243, in Combination With Radiotherapy for YAP1 and BEND3 Biomarker-Defined Small Cell Lung Cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have